Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | NAAA | Q02083 | 2/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11860786 | 0.94 | CYP1A2 (0.38) | CYP2D6CYP1A2NAAACCR2NR1I2 | |
| SCHEMBL29107866 | 0.84 | CYP2D6 (0.47) | CYP2D6CA1CA2CA4KMT2A | |
| SCHEMBL30636633 | 0.82 | CYP2D6 (0.41) | CYP2D6CA1CA2CA4KMT2A | |
| SCHEMBL13548376 | 0.82 | CYP2D6 (0.41) | CYP2D6CA1CA2CA4KMT2A | |
| SCHEMBL486895 | 0.81 | CYP2D6 (0.40) | CYP2D6CA1CA2CA4KMT2A | |
| SCHEMBL1238202 | 0.81 | CYP2D6 (0.43) | CYP2D6 | |
| SCHEMBL11903954 | 0.79 | CYP2D6 (0.43) | CYP2D6 | |
| SCHEMBL8899342 | 0.79 | CYP2D6 (0.46) | CYP2D6CA1CA2CA4KMT2A | |
| SCHEMBL26553377 | 0.79 | CYP1A2 (0.38) | KMT2ACYP1A2NAAACCR2 | |
| SCHEMBL23907959 | 0.78 | CYP2D6 (0.43) | CYP2D6CA1CA2CA4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336868-A1 | COMPOSITIONS COMPRISING ADAMANTYL ESTER-CONTAINING COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2024-10-10 | — | — | US | disclosed |
| EP-1178031-B1 | PROCESS FOR THE PREPARATION OF ORGANIC COMPOUNDS WITH MANGANESE CATALYSTS OR THE LIKE | DAICEL CHEM (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-6548713-B2 | Efficiently producing a compound having an alkyl group or alkenyl group bonded at the alpha position of an electron attractive group, by catalytic radical addition reaction with compound of Group 5,6,7,8, or 9 | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-04-15 | — | — | US | disclosed |
| US-20020165416-A1 | Process for the preparation of organic compounds with manganese cataylsts or the like | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-07 | — | — | US | disclosed |
| EP-1178031-A1 | PROCESS FOR THE PREPARATION OF ORGANIC COMPOUNDS WITH MANGANESE CATALYSTS OR THE LIKE | Daicel Chemical Industries, Ltd. (JP) | 2002-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165416-A1 | Process for the preparation of organic compounds with manganese cataylsts or the like | SOD1, CAT, SOD3 | CYP2D6 1419/4885CA1 1250/4885CA2 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.